Novel Quintuple Agonist Reverses Obesity and Diabetes in Mice

Current treatments for obesity and type 2 diabetes often target single or dual hormone receptors like GLP-1R and GIPR. While effective, these therapies, especially those involving GLP-1R agonism, can lead to significant gastrointestinal adverse effects. Researchers have explored co- and tri-agonists (e.g., GLP-1R:GIPR:GCGR triagonists like Retatrutide) to improve efficacy, but the challenge of side effects persists. This study addresses whether obesity and diabetes can be effectively treated with a broader multi-receptor approach that potentially mitigates common side effects.

The study demonstrated that the novel GLP-1R-GIPR-PPARα/γ/δ quintuple agonism strategy was highly effective in addressing metabolic disorders. > The quintuple agonist successfully corrected obesity and enhanced glycemia in DIO mice, indicating a comprehensive improvement in both weight management and blood sugar control. This multi-targeted approach showed superior efficacy compared to earlier dual or triple agonists, suggesting that engaging PPAR pathways alongside gut hormone receptors provides a more robust metabolic correction. Specifically, the strategy was able to normalize body weight even in obese GLP-1R KO mice, highlighting its ability to bypass or compensate for the absence of GLP-1R signaling, which is often a cornerstone of current therapies. The findings suggest a powerful synergistic effect from targeting these five distinct pathways, leading to significant improvements in metabolic health.